Pharmaceutical Preparations · D8 · CIK 1935979
Biohaven discovers, develops, and commercializes life-changing treatments in immunology, neuroscience, and oncology
Comparable business profile · signals at a glance
In the 90 days to Nov 17, 2025: 4 insiders bought $30.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 17, 2025 | Clark George C.VP, Chief Accounting Officer | Buy | 17,000 | $8.52 | $145K |
| Nov 13, 2025 | Childs John WDirector | Buy | 3,333,333 | $7.50 | $25.0M |
| Nov 13, 2025 | Bailey GregoryDirector | Buy | 400,000 | $7.50 | $3.0M |
| Nov 13, 2025 | Coric VladChief Executive Officer | Buy | 333,333 | $7.50 | $2.5M |
| Mar 4, 2025 | Childs John WDirector | Buy | 28,400 | $30.43 | $864K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Coverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗